Hikal Limited has scheduled its 38th AGM for September 23, 2026, marking a major leadership transition as Founder Jai Hiremath steps down. The company reported a net loss of Rs 487 million for FY 2025-26, impacted by US FDA regulatory actions and asset impairments at its Panoli facility. Investors should watch for the proposed appointment of Sameer Hiremath as CMD and progress on operational remediation.
Hikal Ltd Leadership Transition and FY 2025-26 Performance
Net Loss: Rs 487 million | Proposed Final Dividend: Rs 0.40 per share
Reader Takeaway: Leadership change and operational remediation are central; shareholders must monitor Panoli facility recovery and FDA status.
What just happened
Hikal Limited has issued its 38th Annual General Meeting notice, set for September 23, 2026. The meeting will formalize the transition of company leadership and finalize dividend payouts. Founder Mr. Jai Hiremath will resign as Executive Chairman on October 1, 2026, with Mr. Sameer Hiremath proposed to take over as Chairman and Managing Director for a five-year term.
Why this matters
The transition follows a challenging fiscal year where the company shifted from a profit of Rs 909 million in FY 2024-25 to a net loss of Rs 487 million in FY 2025-26. Revenue declined to Rs 17,249 million from Rs 18,648 million, reflecting the impact of regulatory hurdles and facility-specific charges.
Financial and Operational Hurdles
Management identified three core factors for the annual loss: US FDA regulatory actions, significant asset impairments at the Panoli facility, and exceptional charges linked to new Labour Code implementations. To mitigate these, the company is actively repurposing Panoli assets—having commissioned one of three production lines—and is progressing on remediation efforts at its Jigani site.
Dividend and Remuneration
The board has proposed a final dividend of Rs 0.40 per share, supplementing the Rs 0.20 interim dividend already distributed, bringing the total for FY 2025-26 to Rs 0.60 per share. The record date for the final dividend is September 4, 2026. Additionally, the board approved a revised remuneration package for Whole-Time Director Mr. Sarangan Suresh.
What to track next
Investors should focus on the commissioning of the remaining two production lines at the Panoli facility and the timeline for full US FDA clearance at the Jigani plant. These operational milestones are essential for restoring EBITDA margins and returning to profitability as suggested by the management outlook.